Privia Health Group (PRVA, Care providers & labs) Stock Valuation & Fair Value
Weak on forward returnsPrivia Health Group (PRVA, Care providers & labs) trades at a current P/E of 99.1, about 31% below its historical normal valuation, with a forward growth estimate of 43.5% and a PEG of 2.28. Priced at its historical normal P/E of 143.6 on the same blended earnings, the 2026-11-06 close of $24.42 corresponds to about $35.40 a share. This is a valuation reference, not a price target.
How to read these numbers: the PEG ratio and current P/E versus normal P/E.
- Price $24.42 at the Nov 6 close, 9.6% above the 20-day average ($22.29) and 16.1% above the 50-day ($21.04).
- RSI (14) at 72.7.
- 52-week range $19.10 to $28.10: the price is 13.1% below the high and 27.9% above the low.
The Street vs SeerForecast
Wall Street's mean price target for PRVA is $31.47 across 17 analysts, 28.9% above the current price. The average analyst rating is Strong Buy. Our SeerForecast read of the same stock, formed without analyst targets: weak on forward returns. When the two disagree, start your digging there.
Valuation flags
- Overbought (RSI 73)
- Misses analyst estimates often (100%)
Verdict history
tickerseer's rating moved from mixed on our tests (2026-07-31) to poor on forward returns (2026-11-02). New rating rules took effect in the week of 2026-11-02, and this rating moved across that change, so part of the move may come from the new rules rather than the company.
Not every point was recorded live. Points marked recalculated are worked out from the metrics tickerseer archived that week.
Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.
Show all 29 readings
Frequently asked questions
Is Privia Health Group stock overvalued?
At a current P/E of 99.1 versus its historical normal P/E of 143.6, Privia Health Group trades about 31% below its typical valuation, with a PEG of 2.28 on 43.5% forward growth. tickerseer currently rates it weak on forward returns.
What is Privia Health Group's fair value and PEG?
Privia Health Group trades at a current P/E of 99.1 against a historical normal P/E of 143.6, a PEG of 2.28, and a forward growth estimate of 43.5%. Priced at its historical normal P/E of 143.6 on the same blended earnings, the 2026-11-06 close of $24.42 corresponds to about $35.40 a share. This is a valuation reference, not a price target.
Has tickerseer's rating of Privia Health Group changed?
tickerseer's rating moved from mixed on our tests (2026-07-31) to poor on forward returns (2026-11-02). New rating rules took effect in the week of 2026-11-02, and this rating moved across that change, so part of the move may come from the new rules rather than the company.
What is the analyst price target for Privia Health Group?
The mean Wall Street price target for Privia Health Group is $31.47 across 17 analysts, 28.9% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.
Industry: Care providers & labs. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and an AI research note where we have one. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.